Consistently, our in vitro findings indicated that IL-17a treatment evidently up-regulated TGF-β1 expression, as well as its down-streaming signals such as MMP2, MMP9, α-SMA, Fibronectin and Vimentin, implying the EMT event in NSCLC cells. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.